中国医药
中國醫藥
중국의약
CHINA MEDICINE
2015年
6期
831-833
,共3页
王琪%李楠%刘敏燕%李春霖%金萌萌%苗新宇%钟文雯%方福生%龚燕平
王琪%李楠%劉敏燕%李春霖%金萌萌%苗新宇%鐘文雯%方福生%龔燕平
왕기%리남%류민연%리춘림%금맹맹%묘신우%종문문%방복생%공연평
糖尿病,2型%磷酸西格列汀%老年%安全
糖尿病,2型%燐痠西格列汀%老年%安全
당뇨병,2형%린산서격렬정%노년%안전
Diabetes mellitus,type 2%Sitagliptin%Elderly%Safety
目的 评价磷酸西格列汀治疗老年2型糖尿病患者的有效性及安全性.方法 收集年龄≥65岁的老年2型糖尿病住院患者108例,在原有降糖方案基础上加用磷酸西格列汀100 mg,1次/d.比较治疗前后患者空腹血糖、餐后血糖和糖化血红蛋白(HbA1c)的变化,并记录服药后不良反应.结果 加用磷酸西格列汀后患者HbA1c由(7.4±1.3)％下降至(6.9±0.7)％,差异有统计学意义(P=0.02);空腹合并餐后高血糖患者加用磷酸西格列汀后空腹血糖、餐后血糖及HbA1c较治疗前均明显下降[空腹血糖:(7.0±1.1)mmol/L比(8.3±1.5) mmol/L,餐后血糖:(9.6 ±0.5)mmol/L比(14.0±3.4) mmol/L,HbA1c:(7.0±0.4)％比(8.1±1.5)％],差异均有统计学意义(均P ＜0.05);患者治疗期间未发生过敏、恶心、呕吐、腹痛、腹泻等不良反应.结论 磷酸西格列汀用于老年2型糖尿病患者具有较好的有效性和安全性.
目的 評價燐痠西格列汀治療老年2型糖尿病患者的有效性及安全性.方法 收集年齡≥65歲的老年2型糖尿病住院患者108例,在原有降糖方案基礎上加用燐痠西格列汀100 mg,1次/d.比較治療前後患者空腹血糖、餐後血糖和糖化血紅蛋白(HbA1c)的變化,併記錄服藥後不良反應.結果 加用燐痠西格列汀後患者HbA1c由(7.4±1.3)％下降至(6.9±0.7)％,差異有統計學意義(P=0.02);空腹閤併餐後高血糖患者加用燐痠西格列汀後空腹血糖、餐後血糖及HbA1c較治療前均明顯下降[空腹血糖:(7.0±1.1)mmol/L比(8.3±1.5) mmol/L,餐後血糖:(9.6 ±0.5)mmol/L比(14.0±3.4) mmol/L,HbA1c:(7.0±0.4)％比(8.1±1.5)％],差異均有統計學意義(均P ＜0.05);患者治療期間未髮生過敏、噁心、嘔吐、腹痛、腹瀉等不良反應.結論 燐痠西格列汀用于老年2型糖尿病患者具有較好的有效性和安全性.
목적 평개린산서격렬정치료노년2형당뇨병환자적유효성급안전성.방법 수집년령≥65세적노년2형당뇨병주원환자108례,재원유강당방안기출상가용린산서격렬정100 mg,1차/d.비교치료전후환자공복혈당、찬후혈당화당화혈홍단백(HbA1c)적변화,병기록복약후불량반응.결과 가용린산서격렬정후환자HbA1c유(7.4±1.3)％하강지(6.9±0.7)％,차이유통계학의의(P=0.02);공복합병찬후고혈당환자가용린산서격렬정후공복혈당、찬후혈당급HbA1c교치료전균명현하강[공복혈당:(7.0±1.1)mmol/L비(8.3±1.5) mmol/L,찬후혈당:(9.6 ±0.5)mmol/L비(14.0±3.4) mmol/L,HbA1c:(7.0±0.4)％비(8.1±1.5)％],차이균유통계학의의(균P ＜0.05);환자치료기간미발생과민、악심、구토、복통、복사등불량반응.결론 린산서격렬정용우노년2형당뇨병환자구유교호적유효성화안전성.
Objective To evaluate the effect and safety of sitagliptin in treatment of type 2 diabetes in elderly patients.Methods One hundred and eight hospitalized elderly patients (≥ 65 years old) with type 2 diabetes were included and administrated with sitagliptin (100 mg daily) besides original therapy.The haemoglobin A1c (HbA1c),fasting blood glucose (FBG) and 2 hour postprandial glucose (2 h PBG) were compared before and after treatment.Results After treatment,the HbA1c decreased from (7.4 ± 1.3)％ to (6.9 ± 0.7)％ (P =0.02).In patients with high fasting hyperglycemia as well as high postprandial hyperglycemia;FBG,2 h PBG and HbA1c were significantly decreased compared with those before treatment [FBG:(7.0 ±1.1) mmol/L vs (8.3 ± 1.5) mmol/L,PBG:(9.6 ± 0.5) mmol/L vs (14.0 ± 3.4) mmol/L,HbA1 c:(7.0 ±0.4) ％ vs (8.1 ± 1.5) ％,P ＜ 0.05].No irritation,nausea,vomiting,abdominal pain,diarrhea and other reactions occurred in all patients during treatment.Conclusion Sitagliptin is effective and safe treating type 2 diabetes in elderly patients.
